Basit öğe kaydını göster

dc.contributor.authorNemutlu, Emirhan
dc.contributor.authorZhang, Song
dc.contributor.authorXu, Yi-Zhou
dc.contributor.authorTerzic, Andre
dc.contributor.authorZhong, Li
dc.contributor.authorDzeja, Petras D.
dc.contributor.authorCha, Yong-Mei
dc.date.accessioned2019-12-16T10:29:14Z
dc.date.available2019-12-16T10:29:14Z
dc.date.issued2015
dc.identifier.issn1071-9164
dc.identifier.urihttps://doi.org/10.1016/j.cardfail.2015.04.005
dc.identifier.urihttp://hdl.handle.net/11655/20074
dc.description.abstractBackground: Heart failure (HF) is associated with ventricular dyssynchrony and energetic inefficiency, which can be alleviated by cardiac resynchronization therapy (CRT). The aim of this study was to determine the metabolomic signature in HF and its prognostic value regarding the response to CRT. Methods and Results: This prospective study consisted of 24 patients undergoing CRT for advanced HF and 10 control patients who underwent catheter ablation for supraventricular arrhythmia but not CRT. Blood samples were collected before and 3 months after CRT. Metabolomic profiling of plasma samples was performed with the use of gas chromatography mass spectrometry and nuclear magnetic resonance. The plasma metabolomic profile was altered in the HF patients, with a distinct panel of metabolites, including Krebs cycle and lipid, amino acid, and nucleotide metabolism. CRT improved the metabolomic profile. The succinate-glutamate ratio, an index of Krebs Cycle activity, improved from 0.58 +/- 0.13 to 2.84 +/- 0.60 (P < .05). The glucose-palmitate ratio, an indicator of the balance between glycolytic and fatty acid metabolism, increased from 0.96 +/- 0.05 to 1.54 +/- 0.09 (P < .01). Compared with nonresponders to CRT, responders had a distinct baseline plasma metabolomic profile, including higher isoleucine, phenylalanine, leucine, glucose, and valine levels and lower glutamate levels at baseline (P < .05). Conclusions: CRT improves the plasma metabolomic profile of HF patients, indicating harmonization of myocardial energy substrate metabolism. CRT responders may have a favorable metabolomic profile as a potential biomarker for predicting CRT outcome.
dc.language.isoen
dc.publisherChurchill Livingstone Inc Medical Publishers
dc.relation.isversionof10.1016/j.cardfail.2015.04.005
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCardiovascular System & Cardiology
dc.titleCardiac Resynchronization Therapy Induces Adaptive Metabolic Transitions in the Metabolomic Profile of Heart Failure
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalJournal Of Cardiac Failure
dc.contributor.departmentAnalitik Kimya
dc.identifier.volume21
dc.identifier.issue6
dc.identifier.startpage460
dc.identifier.endpage469
dc.description.indexWoS


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster